Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BBP-711 · 1 trial · 1 indication
Incidence of Adverse Events (AEs)
| Arm | Type | Description |
|---|---|---|
| BBP-711 for SAD | EXPERIMENTAL | A single dose of BBP-711 will be administered orally. |
| Placebo for SAD | PLACEBO_COMPARATOR | A single dose of matching placebo will be administered orally. |
| BBP-711 for MAD | EXPERIMENTAL | A dose of BBP-711 will be administered orally for multiple days. |
| Placebo for MAD | PLACEBO_COMPARATOR | A dose of matching placebo will be administered orally for multiple days. |
| BBP-711 for SAD Food Effect | EXPERIMENTAL | A single dose of BBP-711 will be administered orally. |
| Placebo for SAD Food Effect | PLACEBO_COMPARATOR | A single dose of matching placebo will be administered orally. |
| Name | Type | Description |
|---|---|---|
| BBP-711 | DRUG | BBP-711, oral suspension |
| Placebo | DRUG | Placebo matching BBP-711 |
Inclusion Criteria: * Adult male or female who is 18 to 65 years old, * Weight \>50 kg and ≤110 kg at Screening * Body mass index (BMI) 20 to 32 kg/m2, inclusive, at Screening * In generally good health * Nonsmoker, or not using tobacco or nicotine-containing products for at least 6 months Exclusi...
BBP-711 is an investigational small molecule being developed by BridgeBio Pharma, Inc. (ticker BBIO). It has been studied in a Phase 1 clinical trial in healthy adult volunteers. The specific disease or condition it is intended to treat has not been disclosed.
BBP-711 is being developed by BridgeBio Pharma, Inc., which trades on the Nasdaq under the ticker BBIO. The company sponsored a Phase 1 study of the compound in healthy adult volunteers in the United States.
BBP-711 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no trials are currently active. The study was titled A Study of BBP-711 (ORF-229) in Healthy Adult Volunteers.
BBP-711 has been studied in one clinical trial, NCT04876924, titled A Study of BBP-711 (ORF-229) in Healthy Adult Volunteers. The Phase 1 trial enrolled 92 participants in the United States, was randomized, double-blind, and placebo-controlled, and has been completed.
Yes, BBP-711 is also known as ORF-229. The Phase 1 trial of the compound was registered under the title A Study of BBP-711 (ORF-229) in Healthy Adult Volunteers, so both names refer to the same investigational small molecule developed by BridgeBio Pharma.
BBP-711 is not approved. It is an investigational small molecule in Phase 1 clinical development, and its only registered trial, NCT04876924, was conducted in healthy adult volunteers and has been completed. No approval status has been established for this compound.